Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Toray Makes $5 Million Strategic Investment in Spectral Diagnostics

Published: Monday, March 11, 2013
Last Updated: Monday, March 11, 2013
Bookmark and Share
Private placement expected to close at the beginning of April, 2013.

Spectral Diagnostics Inc. has announced that it has entered into a private placement agreement with Toray Industries, Inc. ("Toray"), pursuant to which Toray will invest $5 million in Spectral.

Under the terms of the private placement (the "Private Placement"), the Company will issue 16,666,667 common shares in the capital of the Company ("Common Shares") to Toray at a price of $0.30 per Common Share, for gross proceeds of $5 million.

The net proceeds of the Private Placement will be used to continue to support the Company's EUPHRATES clinical trial and for general corporate purposes.

Following the closing of the Private Placement, Toray's investment will represent approximately 12.8% of the issued and outstanding Common Shares, calculated on a non-diluted basis.

Under the terms of the Private Placement, Toray will be entitled to nominate one director to the Spectral board for as long as it holds 10% or more of the issued and outstanding Common Shares (calculated on a non-diluted basis).

"This strategic investment not only provides additional funds for our clinical trial, but also strengthens the existing collaborative relationship we have with Toray," said Anthony Businskas, Executive Vice President and CFO of Spectral.

Businskas continued, "We will work with Toray to complete clinical research for U.S. FDA market approval of Toraymyxin, and we will seek to further expand acceptance of the EAATM/ Toraymyxin theranostic in jurisdictions outside of Japan."

Closing of the Private Placement is subject to the approval of the Toronto Stock Exchange and other customary closing conditions. The Private Placement is currently expected to close at the beginning of April, 2013.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

U.S. FDA Approves Spectral's Amended Protocol for its EUPHRATES Trial
Additional exclusion criterion added to the clinical protocol.
Thursday, June 05, 2014
Spectral Updates Status of EUPHRATES Trial
Trial to continue with a total of 650 patients.
Tuesday, April 15, 2014
Spectral Announces Fourth Quarter and Fiscal 2013 Results
Company announces fourth quarter highlights and financial review.
Tuesday, April 01, 2014
Spectral Diagnostics Provides Clinical Update on the Euphrates Trial
Company has scheduled the next DSMB meeting for early April 2014.
Thursday, March 13, 2014
Spectral Announces Status of Second Interim Analysis
DSMB evaluates the safety, efficacy and futility of Company’s EUPHRATES trial.
Friday, January 31, 2014
Spectral Announces Third Quarter 2013 Results
Company to disclose information from the second interim analysis in early 2014.
Monday, November 18, 2013
Spectral Announces Second Quarter 2013 Results
Appointment of Dr. Gualtiero Guadagni as the Company's Vice President.
Wednesday, August 14, 2013
Spectral Provides Update on its EUPHRATES Trial
Trial is on track and continues to enroll patients at an accelerated rate.
Monday, August 05, 2013
Spectral Appoints Vice President of Sales and Marketing
Appointment of Dr. Gualtiero Guadagni as the Company's Vice President.
Tuesday, July 09, 2013
Spectral Announces First Quarter 2013 Results
Company's Phase III EUPHRATES trial enrolled by the end of 2014.
Thursday, May 16, 2013
Spectral Announces Results of First Interim Analysis by Data Safety and Monitoring Board
Enrolment in the EUPHRATES trial is continuing with no safety issues.
Wednesday, February 06, 2013
Spectral Announces Third Quarter 2012 Results
U.S. FDA approved an amended protocol for Spectral's Phase III EUPHRATES trial.
Friday, November 16, 2012
Spectral Announces Second Quarter 2012 Results
Spectral to double the number of trial sites for the Company's personalized medicine approach to treating septic shock.
Friday, August 17, 2012
Spectral Diagnostics Provides Update on Euphrates Trial
FDA allows Spectral to double the number of trial sites for the Company's personalized medicine approach to treating septic shock.
Monday, June 25, 2012
Spectral Diagnostics to Present at BioFinance 2012
Conference to be held at the St. Andrew's Club & Conference Centre in Toronto, Ontario.
Monday, May 21, 2012
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos